Toppila-Salmi Sanna, Hällfors Jenni, Aakko Juhani, Mannerström Bettina, Nieminen Kaisa, Telg Gunilla, Lehtimäki Lauri
Department of Allergology Department of Pulmonary Medicine, Heart and Lung Center Skin and Allergy Hospital Helsinki University Hospital and University of Helsinki Helsinki Finland.
Medaffcon Oy Espoo Finland.
Clin Transl Allergy. 2022 Oct 9;12(10):e12200. doi: 10.1002/clt2.12200. eCollection 2022 Oct.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is commonly associated with asthma. Treatment of CRSwNP includes intranasal and systemic corticosteroids, with non-responsive patients commonly considered for endoscopic sinus surgery (ESS). This nationwide register-based study evaluated the incidence, prevalence, and treatment burden of CRSwNP in Finland, and their association with the presence and severity of comorbid asthma.
Electronic health records of patients diagnosed with CRSwNP between 1.1.2012 and 31.12.2018 in Finnish specialty and primary care were included in the study. The patients were divided into subgroups based on presence, severity, and control of asthma: no asthma, mild to moderate asthma, severe controlled asthma, and severe uncontrolled asthma. A mean cumulative count of ESS was calculated over time per subgroup.
The prevalence of CRSwNP increased from 602.2 to 856.7 patients per 100,000 population between years 2012 and 2019 ( < 0.001). A total of 18,563 patients (59.9% male) had incident CRSwNP between 2012 and 2019, with 27% having asthma, 6% having severe asthma, and 1.5% having severe uncontrolled asthma. In the no asthma, severe controlled asthma, and severe uncontrolled asthma subgroups, systemic corticosteroids were used by 54.1%, 94.9% and 99.3% ( < 0.001), respectively, while the ESS count 3 years post diagnosis was 0.49, 0.68 and 0.80, respectively.
The prevalence of CRSwNP showed a significant increase in the recent decade in Finland. Comorbid asthma, and in particular severe asthma, increased the probability of receiving systemic corticosteroids and undergoing ESS. Thus, improved management of CRSwNP in patients with comorbid asthma is urgently needed.
伴有鼻息肉的慢性鼻-鼻窦炎(CRSwNP)通常与哮喘相关。CRSwNP的治疗包括鼻内和全身使用糖皮质激素,对于无反应的患者通常考虑进行鼻内镜鼻窦手术(ESS)。这项基于全国登记系统的研究评估了芬兰CRSwNP的发病率、患病率和治疗负担,以及它们与合并哮喘的存在和严重程度的关联。
研究纳入了2012年1月1日至2018年12月31日期间在芬兰专科和初级保健机构诊断为CRSwNP的患者的电子健康记录。根据哮喘的存在、严重程度和控制情况将患者分为亚组:无哮喘、轻度至中度哮喘、重度控制哮喘和重度未控制哮喘。计算每个亚组随时间的ESS平均累积次数。
2012年至2019年间,CRSwNP的患病率从每10万人口602.2例增加到856.7例(P<0.001)。2012年至2019年间,共有18563例患者(59.9%为男性)发生CRSwNP,其中27%患有哮喘,6%患有重度哮喘,1.5%患有重度未控制哮喘。在无哮喘、重度控制哮喘和重度未控制哮喘亚组中,分别有54.1%、94.9%和99.3%的患者使用了全身糖皮质激素(P<0.001),而诊断后3年的ESS次数分别为0.49、0.68和0.80。
芬兰近十年来CRSwNP的患病率显著增加。合并哮喘,尤其是重度哮喘,增加了接受全身糖皮质激素治疗和进行ESS的可能性。因此,迫切需要改善合并哮喘患者的CRSwNP管理。